What is the current valuation of the US chorea market in 2024?

The overall market valuation was $168.0 Million in 2024. Read More

What is the projected market valuation for the US chorea market by 2035?

The projected valuation for 2035 is $346.0 Million. Read More

What is the expected CAGR for the US chorea market during the forecast period 2025 - 2035?

The expected CAGR for the US chorea market during the forecast period 2025 - 2035 is 6.79%. Read More

Which companies are the key players in the US chorea market?

Key players in the market include Teva Pharmaceutical Industries Ltd, Bristol-Myers Squibb Company, AbbVie Inc, Novartis AG, Roche Holding AG, Sanofi, Pfizer Inc, and Eli Lilly and Company. Read More

What are the main segments of the US chorea market?

The main segments include types, treatments, distribution channels, symptoms, and end-users. Read More

How much revenue did Huntington's disease generate in the US chorea market in 2024?

Huntington's disease generated $100.0 Million in 2024, with projections reaching $210.0 Million. Read More

What is the revenue range for medical care in the US chorea market?

Medical care revenue ranged from $100.0 Million to $210.0 Million in 2024. Read More

What symptoms are associated with chorea, and what revenue did they generate?

Symptoms such as involuntary muscle movements and speech problems generated revenues ranging from $50.4 Million to $106.0 Million. Read More

What is the revenue range for hospitals as end-users in the US chorea market?

Hospitals as end-users generated revenue ranging from $70.0 Million to $140.0 Million. Read More

US Chorea Market

Q: What distribution channels are utilized in the US chorea market?

Distribution channels include hospitals, clinics, diagnostic centers, drug stores, pharmacies, and others. Read More

US Chorea Market Research Report By Distribution Channel (hospitals, clinics, diagnostic centers, drug stores, pharmacies, others), By Symptoms (involuntary muscle movements, milkmaid's grip, speech problems, seizures), By End User (clinics, hospitals, ambulatory surgical centers, others), By Product Type (Medication, Surgery therapy) and By Treatment (Medical care, Surgical care) - Growth & Industry Forecast 2025 To 2035

Forecast Period

2025 - 2035

CAGR

6.79%

2024 Market Size

$ 168 Million

2035 Market Size

$ 346 Million

Healthcare ● Updated August 2026 Report ID: MRFR/HC/18064-HCR | Pages: 100 | Author: Satyendra Maurya, Garvit Vyas

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Industrial Automation & Equipment, BY Type (USD Million)
  1. 4.1.1 Huntington's disease
  2. 4.1.2 Rheumatic (Sydenham's Chorea)
  3. 4.1.3 Drug-induced Chorea
2. 4.2 Industrial Automation & Equipment, BY Treatment (USD Million)
  1. 4.2.1 Medical care
  2. 4.2.2 Surgical care
3. 4.3 Industrial Automation & Equipment, BY Distribution Channel (USD Million)
  1. 4.3.1 Hospitals
  2. 4.3.2 Clinics
  3. 4.3.3 Diagnostic centers
  4. 4.3.4 Drug stores
  5. 4.3.5 Pharmacies
  6. 4.3.6 Others
4. 4.4 Industrial Automation & Equipment, BY Symptoms (USD Million)
  1. 4.4.1 Involuntary muscle movements
  2. 4.4.2 Milkmaid's grip
  3. 4.4.3 Speech problems
  4. 4.4.4 Seizures
5. 4.5 Industrial Automation & Equipment, BY End-Users (USD Million)
  1. 4.5.1 Clinics
  2. 4.5.2 Hospitals
  3. 4.5.3 Ambulatory surgical centers
  4. 4.5.4 Others
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Industrial Automation & Equipment
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Industrial Automation & Equipment
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Teva Pharmaceutical Industries Ltd (IL)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Bristol-Myers Squibb Company (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 AbbVie Inc (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Novartis AG (CH)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Roche Holding AG (CH)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Sanofi (FR)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Pfizer Inc (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Eli Lilly and Company (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 US MARKET ANALYSIS BY TYPE
3. 6.3 US MARKET ANALYSIS BY TREATMENT
4. 6.4 US MARKET ANALYSIS BY DISTRIBUTION CHANNEL
5. 6.5 US MARKET ANALYSIS BY SYMPTOMS
6. 6.6 US MARKET ANALYSIS BY END-USERS
7. 6.7 KEY BUYING CRITERIA OF INDUSTRIAL AUTOMATION & EQUIPMENT
8. 6.8 RESEARCH PROCESS OF MRFR
9. 6.9 DRO ANALYSIS OF INDUSTRIAL AUTOMATION & EQUIPMENT
10. 6.10 DRIVERS IMPACT ANALYSIS: INDUSTRIAL AUTOMATION & EQUIPMENT
11. 6.11 RESTRAINTS IMPACT ANALYSIS: INDUSTRIAL AUTOMATION & EQUIPMENT
12. 6.12 SUPPLY / VALUE CHAIN: INDUSTRIAL AUTOMATION & EQUIPMENT
13. 6.13 INDUSTRIAL AUTOMATION & EQUIPMENT, BY TYPE, 2024 (% SHARE)
14. 6.14 INDUSTRIAL AUTOMATION & EQUIPMENT, BY TYPE, 2024 TO 2035 (USD Million)
15. 6.15 INDUSTRIAL AUTOMATION & EQUIPMENT, BY TREATMENT, 2024 (% SHARE)
16. 6.16 INDUSTRIAL AUTOMATION & EQUIPMENT, BY TREATMENT, 2024 TO 2035 (USD Million)
17. 6.17 INDUSTRIAL AUTOMATION & EQUIPMENT, BY DISTRIBUTION CHANNEL, 2024 (% SHARE)
18. 6.18 INDUSTRIAL AUTOMATION & EQUIPMENT, BY DISTRIBUTION CHANNEL, 2024 TO 2035 (USD Million)
19. 6.19 INDUSTRIAL AUTOMATION & EQUIPMENT, BY SYMPTOMS, 2024 (% SHARE)
20. 6.20 INDUSTRIAL AUTOMATION & EQUIPMENT, BY SYMPTOMS, 2024 TO 2035 (USD Million)
21. 6.21 INDUSTRIAL AUTOMATION & EQUIPMENT, BY END-USERS, 2024 (% SHARE)
22. 6.22 INDUSTRIAL AUTOMATION & EQUIPMENT, BY END-USERS, 2024 TO 2035 (USD Million)
23. 6.23 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TYPE, 2025-2035 (USD Million)
  2. 7.2.2 BY TREATMENT, 2025-2035 (USD Million)
  3. 7.2.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Million)
  4. 7.2.4 BY SYMPTOMS, 2025-2035 (USD Million)
  5. 7.2.5 BY END-USERS, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

US Chorea Market Segmentation

US Chorea Market By Type (USD Million, 2025-2035)

Huntington's disease
Rheumatic (Sydenham's Chorea)
Drug-induced Chorea

US Chorea Market By Treatment (USD Million, 2025-2035)

Medical care
Surgical care

US Chorea Market By Distribution Channel (USD Million, 2025-2035)

Hospitals
Clinics
Diagnostic centers
Drug stores
Pharmacies
Others

US Chorea Market By Symptoms (USD Million, 2025-2035)

Involuntary muscle movements
Milkmaid's grip
Speech problems
Seizures

US Chorea Market By End-Users (USD Million, 2025-2035)

Clinics
Hospitals
Ambulatory surgical centers
Others

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”